Capital Flow Monitor · Sponsors · CIK 1937993
Cadrenal Therapeutics, Inc.
822 A1A NORTH, SUITE 306, PONTE VEDRA, FL, 32082 · (904) 300-0701
Biotechnology · Corporation· inc. DELAWARE true 2022
Fit score
—
Offering
$8.8M
Sold
$8.8M
% sold
100.0%
Investors
1
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-07-15 | D ·current | 506(b) | $8.8M | $8.8M | 100.0% | 1 | EDGAR ↗ |
| 2026-04-06 | D | 506(b) | $7.9M | $7.9M | 100.0% | 1 | EDGAR ↗ |
| 2025-12-31 | D | 506(b) | $4.4M | $4.4M | 100.0% | 4 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed.
- Quang X. Pham — Executive Officer / Director, Ponte Vedra, FL
- John P. Sharp — Executive Officer, Ponte Vedra, FL
- James J. Ferguson — Executive Officer, Ponte Vedra, FL
- Jeffrey S. Cole — Executive Officer, Ponte Vedra, FL
- Lee Golden — Director, Ponte Vedra, FL
- John R. Murphy — Director, Ponte Vedra, FL
- Glynn Wilson — Director, Ponte Vedra, FL
Placement agents
- H.c. Wainwright & Co., Llc · 0 RE raises
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.